GO
Loading...

Enter multiple symbols separated by commas

Sanofi SA

More

  • From school in the late 1970 s and 1980 s, when only elite students gained entry into China's few biochemistry and molecular biology programs, they left China, graduated and worked their way up to senior positions in the world's top pharmaceutical companies. For decades, China tried to woo them home, but they were reluctant to return to a cloistered, politicized...

  • Feb 10- Regeneron Pharmaceuticals Inc reported better-than-expected fourth-quarter sales, driven by surging demand for its blockbuster eye drug Eylea. The biotechnology company's net profit rose to $110.2 million, or 96 cents per share, in the fourth quarter ended Dec. 31 from $96.8 million, or 86 cents per share, a year earlier. Revenue, including...

  • Feb 10- Regeneron Pharmaceuticals Inc reported a nearly 14 percent jump in quarterly profit, driven by strong demand for its blockbuster eye drug Eylea. The biotechnology company's net profit rose to $110.2 million, or 96 cents per share, in the fourth quarter ended Dec. 31 from $96.8 million, or 86 cents per share, a year earlier. Revenue, including collaboration...

  • Europe ends flat after ECB decision; Greece weighs Thursday, 5 Feb 2015 | 11:45 AM ET

    European equities ended lower on Thursday after the European Central Bank put more pressure on Greece.

  • Europe shares fall after ECB decision on Greek debt Thursday, 5 Feb 2015 | 3:08 AM ET

    PARIS, Feb 5- European stocks fell early on Thursday after the European Central Bank abruptly canceled its acceptance of Greek bonds in return for funding, shifting the burden onto the country's central bank. The ECB move, which required the support of a majority of central bank chiefs across the euro zone, shows widespread dismay with the new Greek government's...

  • *Weinberg says has stabilized Lantus market share in United States. PARIS, Feb 5- French drugs firm Sanofi said on Thursday it would be in a position to name a new chief executive in the coming weeks as it delivered 1.5 percent quarterly earnings per share growth thanks to the weak euro. "The announcement will be before the end of the first quarter," said Chairman Serge...

  • Weak euro boosts Sanofi earnings, to name CEO in Q1 Thursday, 5 Feb 2015 | 1:33 AM ET

    PARIS, Feb 5- Sanofi said on Thursday it would be in a position to name a new chief executive by the end of the first quarter as it delivered fourth-quarter earnings boosted by the weak euro. The drugs company, which sacked Chris Viehbacher as CEO last year, nevertheless said it would need the euro to stay weak to ensure significant earnings growth this year.

  • CHICAGO, Feb 4- After successfully treating four Ebola patients last year, Emory University in Atlanta is now leading a government-funded project that will use blood from survivors of the deadly virus to test a novel way of treating infectious disease. The Defense Advanced Research Projects Agency, the Pentagon's elite research arm, has awarded Emory up to...

  • Feb 3- Isis Pharmaceuticals Inc's experimental diabetes drug took a longer-than-expected 36 weeks to reduce blood sugar levels in patients with type 2 diabetes. Deutsche Bank's Alethia Young said the data looked less robust that some commonly prescribed treatments and Isis's own experimental glucagon receptor, ISIS-GCGR. Type 2 diabetes is a chronic...

  • Early movers: UPS, WEN, RSH, AET, SPLS & more Tuesday, 3 Feb 2015 | 8:11 AM ET
    NYSE exchange floor

    Some of the names on the move ahead of the open.

  • Feb 3- Isis Pharmaceuticals Inc said its experimental diabetes drug was effective in reducing the body weight and blood sugar in patients with type 2 diabetes. The drug, ISIS-PTP1B, was tested against a placebo in a mid-stage study comprising 92 type 2 diabetes patients with uncontrolled blood sugar, despite treatment. Type 2 diabetes is a chronic condition...

  • No more needles: Inhaled insulin debuts in US Tuesday, 3 Feb 2015 | 6:22 AM ET
    A Sanofi lab worker packages vaccines against the flu.

    Sanofi launched an inhalable insulin in the U.S. in a potential boost for its flagging diabetes drug sales and for patient quality of life.

  • Sanofi launches inhaled insulin for diabetics Tuesday, 3 Feb 2015 | 1:00 AM ET

    PARIS, Feb 3- Sanofi launched an inhalable insulin in the United States on Tuesday in a potential boost for its flagging diabetes drug sales and for patient quality of life. Developed by Mannkind Corp, Afrezza will be the only inhalable insulin on the U.S. market, where Sanofi competes with Eli Lilly and Novo Nordisk for sales of traditional injectable insulin.

  • Stocks close up sharply, boosted by Greece and oil Monday, 2 Feb 2015 | 4:00 PM ET
    Traders work on the floor of the New York Stock Exchange.

    U.S. stocks closed sharply higher on encouraging news from the Eurozone and stronger oil prices.

  • *Sanofi struggling to find new CEO in narrow field. PARIS, Jan 30- Barring a last-minute breakthrough, drugs firm Sanofi's Chairman Serge Weinberg may have to acknowledge in his results presentation next week that the hunt for a new chief executive is not going well. Paris- schooled Olivier Bohuon, chief executive of British medical devices maker Smith& Nephew,...

  • BERLIN, Jan 27- International donors pledged $7.5 billion on Tuesday to immunize 300 million children in poor countries against deadly diseases such as diarrhea and pneumonia. At a Global Alliance for Vaccines and Immunization conference in Berlin, Microsoft founder Bill Gates and the British government topped the donations list at $1.55 billion and $1.5...

  • LONDON, Jan 26- Pfizer is to cut the price of its pneumococcal vaccine Prevenar 13 by 6 percent to $3.10 per dose in poor countries as part of a commitment to the GAVI global vaccines alliance, the U.S. drugmaker said on Monday. Pfizer's move comes as GAVI holds a major funding conference in Berlin at which it hopes to raise $7.5 billion from donors to pay for increased...

  • DAVOS, Switzerland, Jan 21- Takeda Pharmaceutical, Japan's largest drugmaker, is ready to look at doing deals now that it has refocused operations, its incoming chief executive said on Wednesday. "We don't want to be passive and we don't want to watch the train passing," he told Reuters on the fringes of the World Economic Forum in Davos. As COO, Weber has overseen a...

  • DAVOS, Jan 21- Christophe Weber, chief operating officer of Takeda Pharmaceutical Co., said on Wednesday he had been approached in connection with the vacant chief executive post at French drugs group Sanofi but decided to stay put. I just arrived and I'm not the kind of guy who would jump like that, "the French national told Reuters on the sidelines of the World...

  • *AstraZeneca sees $3.5 bln sales, analysts' numbers lower. *AstraZeneca shares up 1.5 percent. LONDON, Jan 14- AstraZeneca's blood-thinning drug Brilinta cut the risk of death or heart attack in patients with a history of previous attacks, according to a major clinical trial that will boost hopes for the closely watched product.